erratum: correction to: evaluating the efficacy and safety of human anti-sars-cov-2 convalescent plasma in severely ill adults with covid-19: a structured summary of a study protocol for a randomized controlled trial (trials (2020) 21 1 (499). An amendment to this paper has been published and can be accessed via the original article.